Redeye sees today's news about the study that has now begun that intends to expand and strengthen the clinical data for PrimECC® as positive. The start of the study is in line with our forecast of a market launch in 2022 in Europe and 2023 in the US. The study is an essential step since Xvivo does not plan any extensive launch of the product before the results from the study have been published. This step was expected but positive, we will not, at this point, make any significant changes to our estimates.